Genetics Squared Names New President/CEO, Bolsters Management For Product Developments 
10/19/2005 5:11:06 PM

ANN ARBOR, Mich., April 29 /PRNewswire/ -- An experienced technology and biotech executive has been named president and chief executive officer of Genetics Squared, a three-year-old life sciences firm that uses computers rather than wet labs for discovery and analysis.

John Freshley, who most recently was director of corporate development and marketing for STATPROBE, a clinical research firm, will assume the new position in a full-time capacity June 15. He joins Bill Worzel, co-founder and chief technical officer, as the early-stage drug development firm broadens its management. Freshley's experience also includes senior management responsibility in software development as well as biotechnology companies. Freshley consulted with Genetics Squared for the past two years to develop its strategic plan.

Speech at BIO Mid-America Venture Forum

Freshley will introduce the firm May 5, 2004 in a speech at the BIO Mid-America Venture Forum in St. Louis.

Earlier, Freshley was an executive with grapevine Technologies, a knowledge management software firm, and Biotherapies, which worked to develop a protein for breast-cancer treatment.

With a strong background in business development, sales and marketing, Freshley broadens the expertise of the firm as it plans to significantly increase its revenues and customer base. He joins Bill Worzel who co-developed the patented technology that the firm uses in its product work.

Patented Technology

The company is focused on using its novel analysis software to rapidly advance clinical development of products by identifying characteristics of patients most likely to respond to new therapies, Freshley explained.

"We have an innovative and proven proprietary and patented technology that solves problems other methods cannot," Freshley explained. "The technology has been tested in pharmaceutical and academic projects and the proof-of-concept is complete," he noted. "We are excited by the opportunity to impact patient treatment by ensuring the right patients get treated with the right therapy at the right time."

Genetics Squared

CONTACT: Larry T. Eiler of Eiler Communications, +1-734-761-3399, or+1-734-646-6593, or, for Genetics Squared